Mabgeek Biotech's MG-K10 for atopic dermatitis has received implied approval of IND in the United States.

2023-10-19

On September 29, 2023, Mabgeek Biotech announced that its IL-4Rα-targeting antibody MG-K10 humanized monoclonal antibody injection (Comekibart) has been approved by the U.S. The study is a multicenter Phase Ib clinical study to evaluate the efficacy of MG-K10 in adults with moderate to severe atopic dermatitis in the United States. Safety, pharmacokinetics and preliminary efficacy.

Mabgeek Biopharma has initiated clinical Phase Ib studies in the United States.

▼Learn more

MG-K10 humanized monoclonal antibody drug (Comekibart)

Mabgeek Bitotech

Shanghai Mabgeek Biotech Co., Ltd. was established in 2016 and is headquartered in Zhangjiang Pharmaceutical Valley. It has R&D laboratories in Shanghai and Nanjing. Mabgeek Biotech mainly focuses on the unmet clinical needs in the fields of allergic inflammatory diseases, autoimmune diseases, etc., and conducts independent research and development and commercialization of innovative antibody drugs through differentiated competitive strategies. Currently, several innovative antibody drugs are in the clinical research stage.

Return to List

News

Mabgeek Biotech's MG-K10 for atopic dermatitis has received implied approval of IND in the United States.

The phase II clinical study of MG-K10 for the treatment of moderate to severe atopic dermatitis has reached its primary endpoint.

The phase II data of the long-acting IL-4R antibody for atopic dermatitis from Mabgeek Biotech was presented at bio Europe 2023, attracting much attention.

About

R&D

Publications

Careers

Contact Us

Cookie Settings